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Objectives The objective of this study was to evaluate the effects of different lesion sets of ablation in patients undergoing
mitral surgery plus maze.
Background The role of lesion sets on outcome after maze is poorly defined.
Methods A total of 141 patients were prospectively followed up. Two different lesion sets were prepared: 32 patients un-
derwent a radiofrequency left atrial lesion set of maze (“limited”), and 109 had combined left and right atrial
lesion sets of maze  ganglionic plexi isolation (“extensive”). A longitudinal observational study assessed the
role of “extensive” versus “limited” ablation on atrial fibrillation (AF), New York Heart Association (NYHA) func-
tional class II/III, treatment with antiarrhythmic drugs, follow-up recovery of the ratio of E- to A-wave (E/A), and
survival and time to hospitalization (overall and for heart failure).
Results The prevalence of AF over time was lower in the “extensive” arm (adjusted relative risk [RR]: 0.10; 95% confi-
dence interval [CI]: 0.03 to 0.31; p  0.001), with significantly lower prevalence at discharge, 3 months, and 18
months. The prevalence of patients in NYHA functional class II/III over time was lower in the “extensive” arm
(adjusted RR: 0.11; 95% CI: 0.03 to 0.34; p  0.001), with significant differences at any assessment (except the
third month). The differences in E/A recovery and use of antiarrhythmic drugs were less marked, with an RR of
1.55 (95% CI: 0.99 to 2.42; p  0.05) and RR of 0.76 (95% CI: 0.54 to 1.06; p  0.11), respectively, with a sig-
nificantly lower prevalence of antiarrhythmic drugs in the “extensive” ablation arm at 12, 18, and 24 months.
Rates of hospitalization for heart failure, overall hospitalization, and the combined event death/hospitalization
were lower in the “extensive” arm (p  0.11, p  0.003, and p  0.002, respectively).
Conclusions The addition of right-sided ablation improves clinical and electrophysiologic results after maze
procedure. (J Am Coll Cardiol 2011;57:931–40) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.055Since Cox proved that atrial fibrillation (AF) could be
treated by means of surgery (1), a growing number of
simplified maze procedures have been proposed (1,2). How-
ever, different percentages of recurrent AF have been
reported and attributed to learning curves, lesion sets,
indications, and peri-operative protocols (1–3). In par-
ticular, the role of the lesion sets has been poorly
investigated (1–3).
Indeed, different lesion sets with radiofrequency have
been developed at our institutions since the original maze
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2010, accepted September 17, 2010.procedure was developed (4). Therefore, it was the aim of
this study to evaluate the mid-term electrophysiological and
clinical results of a consecutive series of patients undergoing
concomitant surgical ablation for AF and mitral valve
surgery with 2 different surgical approaches—an “extensive”
and a “limited” approach—during the last 5 years at 2
universities.
Methods
Population. From April 2003 to September 2008, we
enrolled 141 consecutive patients who underwent mitral
surgery and concomitant surgical ablation for longstanding,
persistent AF (according to the Heart Rhythm Society/
European Heart Rhythm Association/European Cardiac
Arrhythmia Society [HRS/EHRA/ECAS]; permanent AF
according to the American College of Cardiology/American
Heart Association) (3). Institutional review board approval
932 Onorati et al. JACC Vol. 57, No. 8, 2011
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tained. Demographics are re-
ported in Table 1.
Surgery. Cardiopulmonary by-
pass and surgery were standard-
ized (4). Operative data are sum-
marized in Table 1.
Five different lesion sets de-
rived from the so-called maze IV
operation (1) were applied during
the study time period (Fig. 1).
However, a “more aggressive” sur-
gical approach also addressing the
right atrium was started in 2004
because macro–re-entrant circuits
sustaining AF occur virtually any-
where in either atrium (1).
“Limited” approach. Fourteen patients (subgroup A1) un-
derwent the left atrial (LA) lesion set of the maze procedure
(Fig. 1A) by means of monopolar radiofrequency (Cardio-
blate Irrigated RF Monopolar Pen and Cardioblate Surgical
Ablation System Generator, Medtronic Inc., Minneapolis,
Minnesota). Almost all of these patients were enrolled early
in the study (April 2003 to January 2004), except for 3
undergoing such a lesion set because of the recurrent nature
of surgery at 10, 12, and 15 months before closure of the
follow-up. Eighteen patients (subgroup A2; December
2003 to September 2007) underwent the previously men-
tioned LA lesion set of maze but with the bipolar clamp
(Cardioblate LP Irrigated Surgical Ablation Device,
Medtronic) (Fig. 1B). Because radiofrequency ablation was
limited to the LA, all of these 32 patients comprised the
“limited” group (group A).
“Extensive” approach. Right atrial ablation was added to
the subgroup A2 lesion set for 38 patients (subgroup B1;
August 2004 to June 2008) (Fig. 1C), and ganglionic plexi
(GP) isolation and fat pad resection was added to the
subgroup B1 lesion set for 32 patients (subgroup B2; June
2005 to May 2008) (Fig. 1D) (4). Thirty-nine patients
(subgroup B3; September 2006 to May 2008) underwent
the subgroup B2 lesion set, but with 4 repetitions of each
line of ablation. Subgroups B1, B2, and B3 also involved the
right atrium and comprised the “extensive” group (n  109;
group B).
The atrial appendages were always excluded by external
ligation and internal stitching.
Peri-operative care and follow-up. Twelve-lead electro-
cardiography (ECG) was performed pre-operatively, on
admission to the intensive therapy unit, and daily thereafter
until hospital discharge or whenever necessary. All patients
underwent continuous electrocardiographic monitoring for
the first 72 h post-operatively.
An intravenous amiodarone bolus (150 mg), followed by
continuous infusion at 1 mg/kg/h for 12 h and then 0.5
mg/kg/h until patients tolerated oral intake, was adminis-
Abbreviations
and Acronyms
AF  atrial fibrillation
AFL  atrial flutter
AT  atrial tachycardia
CHF  congestive heart
failure
E/A  ratio of E- to A-wave
GP  ganglionic plexi
LA  left atrial/atrium
NYHA  New York Heart
Association
SR  sinus rhythmtered intraoperatively. Then oral amiodarone (200 mgtwice/day for 1 week and then 200 mg daily) was adminis-
tered until patient discharge.
Follow-up data were collected in the outpatient clinic (at
7 days, 14 days, 1 month, 3 months, 6 months, 1 year, and
then once per year or whenever requested). Follow-up
telephone calls with patients and cardiologists were made
whenever necessary. A 24-h Holter ECG was performed at
the 1-, 3-, 6-, 12-, 18-, 24-, 36-, 48-, and 60-month
follow-ups. The New York Heart Association (NYHA)
functional class was collected at the same time points.
After hospital discharge, general practitioners or referral
cardiologists chose to continue amiodarone, switch to
propafenone or beta-blocking agents, or stop antiarrhythmic
medications after the sixth month. Accordingly, use of
antiarrhythmic drugs defined the use of Class Ic/II/III drugs
at each follow-up interval. An initial post-ablation blanking
period of 3 months was considered: the reported recurrences
defined “early events” (3).
Recovery of the E- to A-wave ratio (E/A) was investi-
gated by trans-thoracic echocardiography in patients main-
taining sinus rhythm at 6-month intervals, starting from the
Presenting and Operative/Peri-OperativeCharac eristics According to Treatment ArmTable 1 Presenting and Oper iv /Peri-OperativeCharacteristics According to Treatment Arm
Characteristic
Limited
Ablation
(n  32)
Extensive
Ablation
(n  109) p Value
At admission
Age (yrs) 65 8 64 9 0.51
Male 18 (56%) 79 (72%) 0.09
Diabetes 10 (31%) 40 (37%) 0.67
Hypertension 15 (47%) 37 (34%) 0.21
Dyslipidemia 8 (25%) 19 (17%) 0.44
Smoking 5 (16%) 20 (18%) 1.0
COPD 7 (22%) 36 (33%) 0.28
Redo surgery 3 (9%) 0 0.01
LAD (mm) 51 4 51 3 0.71
LVEF (% [Simpson method]) 46 6 46 5 0.64
Duration of AF (months) 15 (13–28) 26 (14–38) 0.08
Operative and peri-operative
Year of surgery
2003 19 (60%) 0 0.001
2004 9 (28%) 16 (15%)
2005 3 (9) 14 (13%)
2006 0 19 (17%)
2007 1 (3%) 47 (43%)
2008 0 13 (12%)
Aortic valve plasty 4 (12%) 8 (7%) 0.64
Aortic valve replacement 4 (12%) 18 (16%)
Mitral valve plasty 23 (72%) 70 (64%) 0.52
Mitral valve replacement 9 (28%) 39 (36%)
Tricuspid plasty 8 (25%) 31 (28%) 0.82
AF at aortic declamping 10 (31%) 24 (22%) 0.35
ACC time (min) 73 7 74 6 0.36
CPB time (min) 110 (102–113) 112 (103–133) 0.10
Values are mean  SD, n (%), or median (25th–75th percentile).
ACC  aortic cross-clamp; AF  atrial fibrillation; COPD  chronic obstructive pulmonarydisease; CPB cardiopulmonary bypass; LAD echocardiographic left atrial diameter; LVEF left
ventricular ejection fraction.
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February 22, 2011:931–40 AF Ablation With Different Lesion Setsthird post-operative month. The E/A ratio measures the
ratio between the passive ventricular filling (early E-wave)
and active filling (atrial A-wave) at pulsed Doppler analysis.
E-wave is physiologically greater than A-wave (E/A 1),
but loss of atrial kick (E/A not measurable) develops with
AF. Ventricular function impacts A-wave but is negligible
after the third post-operative month (5). Thus, the recovery
of atrial transport function is measurable from the third
post-operative month by means of a recovered E/A 1 (5).
pisodes of congestive heart failure (CHF) were recorded
hroughout the follow-up.
Follow-up was closed on March 30, 2009, and was 100%
ompleted.
tudy design. The primary efficacy end point was freedom
rom AF/atrial flutter (AFL)/atrial tachycardia (AT) for at
east 30 s without antiarrhythmic drug therapy, according to
he HRS/EHRA/ECAS (3). Secondary end points were
Figure 1 Lesion Sets
(A) Solid lines represent the unipolar radiofrequency ablations aimed at encircling
(lines between RPV and LPV; also called box lesion), isolating the left atrial appen
lesion) and the connection line between the box lesion and the LAA. (B) The sam
(dotted lines). (C) The right atrial lesion set of maze was added to the left lesion
connecting PS with both superior [SVC] and inferior vena cava [IVC]) and 1 for isol
the inferior isthmus between IVC and the tricuspid valve (TV) annulus and 1 conne
isthmus). Isolation of the right atrial appendage (RAA) and terminal crest (TC) (cur
used, adding ganglionic plexi (GP) (solid black circles) isolation (dotted lines) alo
for GP located on the right side along the RPVs; isolation of left-sided GP is indica
B3 is not reported because the lesion sets of D were applied, with 4-time deliveryollow-up survival; freedom from AF/AFL/AT with anti- wrrhythmic therapy; freedom from only AF; prevalence of
early events”; and heart rhythm at aortic declamping,
ischarge, and 6, 12, 18, and 24 months post-operatively, as
equested by the HRS/EHRA/ECAS (3). A longitudinal
bservational study aimed at assessing the role of “extensive”
ersus “limited” ablation on survival, time to first hospital-
zation (overall and for CHF), and prevalence of AF during
ollow-up was conducted. Given the variability of the
unctional classes, drug regimens, and recovery of atrial
ransport function observed during the follow-up, different
ongitudinal analyses aimed at assessing the role of ablation
n the prevalence of NYHA functional class II or III
defined by episodes of CHF), treatment with antiarrhyth-
ic drugs, and recovery at E/A were conducted.
tatistical analysis. Pre- and peri-operative data are shown
s mean and SD, median and 25th to 75th percentile if
ontinuous, and counts and percentage if categoric. They
right pulmonary veins (RPVs) and left pulmonary veins (LPVs), closing the antrum
LAA), and ablating the left isthmus (line connecting the mitral valve [MV] and box
n set in A was adopted, except for the use of bipolar radiofrequency energy
B: 2 purse-string sutures (PS) were applied, 1 for intercaval lesion (dotted line
f the cavo-tricuspid isthmus (dotted lines starting from the other PS: 1 ablating
he PS with the TV annulus above the coronary sinus (CS) to ablate the septal
tted line above) completed the scheme. (D) The same lesion set in C was
Waterston groove (WG), between the left atrium (LA) and the right atrium (RA),
dotted lines along the LPVs and the Marshall ligament (ML) of the LA. Subgroup
olar radiofrequency energy. LV  left ventricle.the 2
dage (
e lesio
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Mann-Whitney U test, and Fisher exact test. Confidence
ntervals (CI) for the risk difference (RD) were normally
pproximated. Median follow-up time was calculated ac-
ording to the inverse Kaplan-Meier method.
Kaplan-Meier cumulative survival and first hospitalization-
ree (for heart failure, any cause, and combined event death/
ospitalization) survival were computed and compared by
eans of a stratified Cox model. Stratification by the pro-
pensity score allowed for separate baseline hazards for
homogeneous groups of patients. Hazard ratios (HRs) and
95% CI are reported. The proportional hazard assumption
was tested (and satisfied) with a test based on Schoenfeld
residuals. Rates of events (per 100 person-years) are re-
ported, with 95% CI. The propensity score was obtained
from a logistic model for treatment, including all pre-
operative characteristics: age, sex, duration of AF, left
ventricular ejection fraction, LA diameter, year of surgery,
diabetes, hypertension, dyslipidemia, smoking habits,
chronic obstructive pulmonary disease, and redo surgery.
Continuous variables were included as linear terms. The
c statistic was computed to 0.96. Six blocks were identified
from the computed propensity score so that the mean
propensity score was not different for the 2 treatment arms
in each block and the balancing properties were satisfied.
A mixed random-effects log linear model was fitted to
compare the prevalence of the outcomes over time. For this
purpose, assessments up to 24 months only were included to
guarantee a sufficient number of patients at each time point
and avoid overfitting. Risk ratios and 95% CI were com-
puted. All models were adjusted for the propensity score
blocks (on a continuous scale) and the presence of AF at
declamping. At each time point, RD and conservative
99.2% CI were calculated. Finally, conditional logistic
regression (conditioned on the propensity score blocks) was
used to assess the association of a series of patient charac-
teristics with the presence of AF/AFL/AT at 6 months.
Crude odds ratios (cORs) and corresponding CIs were
computed. Stata version 11 (Stata Corporation, College
Station, Texas) was used for computation. Two-sided p 
0.05 was considered statistically significant. Post-hoc com-
parisons at each time point and for subgroups were adjusted
for multiplicity with the Bonferroni correction. Subgroup
analyses are to be considered as descriptive only.
Results
Pre- and peri-operative assessments. Patient characteris-
tics were similar in the 2 groups, except for the year of
surgery (p  0.001) and recurrence (p  0.011) (Table 1).
No patient died peri-operatively in the “limited” compared
ith 4 in the “extensive” ablation group (RD: 3.7%; 95% CI:
.1% to 7.2%; Fisher exact test p 0.57). Twenty-five patients
18%) experienced in-hospital morbidity. Again, peri-operative
orbidity was comparable between the 2 groups (“limited”: n 722%] vs. “extensive”: n  18 [16%]; RD: 8.5%; 95% CI: w24.3% to 7.2%; p  0.27). No AF surgery–related
omplications were recorded.
ost-operative cardiac rhythm and freedom from AF/
FL/AT. On aortic declamping, 81 patients (58%) recov-
red sinus rhythm (SR), 26 (18%) were in junctional
hythm, thus requiring temporary pacemaker stimulation,
nd 34 (24%) displayed AF. Notably, AF at declamping was
ore frequent, although not significantly, in the “limited”
blation group (Table 1) (RD: 9.2%; 95% CI: 8.6% to
7.1%; p  0.35). Five patients demonstrating junctional
hythm at declamping (4% of survivors) required definitive
acemaker implantation. All patients were treated with
miodarone post-operatively, with 119 (87%) discharged
ome in SR and the remaining 13 (9%) in longstanding,
ersistent AF. Four patients (3%) developed post-
perative transient type 1 AFL during hospitalization,
ut all recovered with intravenous amiodarone and were
ischarged in SR.
ong-term event-free survival. Five patients each died in
he “limited” and “extensive” treatment arms during a
edian follow-up of 30 months (25th to 75th: 17 to 50
onths). A lower mortality (although nonsignificant) was
bserved in the “extensive” versus “limited” ablation arm
2.1 [95% CI: 0.9 to 5.0] vs. 3.6 deaths per 100 person-years
95% CI: 1.5 to 8.6]; stratified HR: 0.23 [95% CI: 0.02 to
.50; p  0.29]). Seven and 8 patients, respectively, were
ospitalized for heart failure, with rates of 3.1 (95% CI: 1.5
o 6.4) versus 6.8 hospitalizations per 100 person-years
95% CI: 3.4 to 13.7) and a stratified HR of 0.23 (95% CI:
.04 to 1.42; p  0.11); 13 and 14 patients, respectively,
ere hospitalized for any cause, with rates of 6.0 (95% CI:
.5 to 10.3) and 14.0 hospitalizations per 100 person-years
95% CI: 8.3 to 23.7) and a stratified HR of 0.11 (95% CI:
.02 to 0.53; p  0.003). For the combined event death or
ospitalization, the stratified HR was 0.12 (95% CI: 0.03 to
.49; p  0.002). Kaplan-Meier survival and event-free
urvival are shown in Figure 2.
The success of the “extensive” procedure on the com-
ined event, in a bivariable stratified Cox model, was
ndependent of the presence of AF at discharge (p 
.87), and the effect of the surgical technique was not
odified by the presence of AF at discharge (p for
nteraction  0.26) (Fig. 3).
Longitudinal assessment. Overall, the prevalence of AF
over time was lower in the “extensive” ablation arm (ad-
justed relative risk [RR]: 0.10; 95% CI: 0.03 to 0.31; p 
0.001) (Table 2). Post-hoc comparisons showed signifi-
cantly lower prevalence (after Bonferroni correction) at
discharge and at 3 and 18 months. Similarly, the prevalence
of patients in NYHA functional class II/III over time was
lower in the “extensive” ablation arm (adjusted RR: 0.11;
95% CI: 0.03 to 0.34; p  0.001), with significant differ-
nces at any time point (except for the third month) (Table
). However, manifest episodes of CHF were recorded only
arely in both the “extensive” and “limited” ablation arms,
ith no significant differences between them (5 [5%] vs. 4
(
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0 vs. 3 [10%)], RD: 10% [99.2% CI: 25% to 5%] at 18
months; and 3 (6%) vs. 1 (4%), RD: 2% [99.2% CI: 11%
to 15%] at 24 months). The differences in E/A recovery and
use of antiarrhythmic drugs were less marked, with an
adjusted RR of 1.55 (95% CI: 0.99 to 2.42; p  0.05) and
0.76 (95% CI: 0.54 to 1.06; p  0.11), respectively.
However, although all patients were taking antiarrhythmic
drugs at discharge and at 3 and 6 months, a significantly
lower use (after Bonferroni correction) of antiarrhythmic
drugs was registered in the “extensive” ablation arm at 12,
18, and 24 months post-operatively (Table 2). As shown in
Figure 4 (for description only), at the 12-, 18-, and
24-month assessments, patients with AF tended to be
taking antiarrhythmic drugs more frequently than patients
without AF. A similar behavior was seen for both the
limited and extensive approaches (Figs. 5A and 5B).
Subgroup analysis. Rates of the combined event (death
and hospitalization) per 100 person-years were 25 (95% CI:
13 to 47), 11 (95% CI: 5 to 23), 7 (95% CI: 3 to 14), 15
(95% CI: 8 to 29), and 4 (95% CI: 1 to 15) in the A1, A2,
Figure 2 Kaplan-Meier Curves According to Treatment Arm (“L
Survival (A). Hospitalization-free survival (heart failure) (B). Hospitalization-free suB1, B2, and B3 ablation subgroups, respectively (Fig. 3)stratified Cox model p  0.001). The introduction of GP
blation (B2 vs. B1) did not significantly modify the risk of
he combined event (HR: 1.01; 97.5% CI: 0.32 to 3.48; p
.93), whereas the introduction of 4 linear ablations (B3 vs.
2) was able to reduce it (HR: 0.19; 97.5% CI: 0.03 to 1.13;
 0.017).
The prevalence of AF at 6 months was 61% (95% CI: 31%
o 92%), 47% (95% CI: 21% to 73%), 26% (95% CI: 11% to
2%), 23% (95% CI: 7% to 39%), and 13% (95% CI: 2% to
4%) in the A1, A2, B1, B2, and B3 ablation subgroups,
espectively (conditional logistic model p  0.001). Neither
he introduction of GP ablation (B2 vs. B1) nor 4 linear
blations (B3 vs. B2) significantly modified this prevalence
cOR: 0.56; 97.5% CI: 0.13 to 2.35; p  0.36 and cOR:
0.48; 97.5% CI: 0.11 to 2.03; p  0.25, respectively).
To explore the issue of a “learning curve” effect, the
prevalence of AF at 6 months in the last 10 patients
undergoing “limited” and the last 10 patients undergoing
“extensive” approaches were computed; the prevalence was
50% (95% CI: 12% to 88%) and 30% (98% CI: 0% to 64%),
respectively, favoring a protective effect of the “extensive”
d” vs. “Extensive” Ablation)
overall) (C). Combined event-free survival (hospitalization or death) (D).imite
rvival (approach. Of note, all models comparing the 2 approaches
936 Onorati et al. JACC Vol. 57, No. 8, 2011
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year of surgery and thus for the used approaches, these being
sequential in time.
Discussion
In this study, we collected our experience with the surgical
ablation procedures for AF developed over the last 5 years,
during which different surgical lesion sets were used. Al-
though a 7-day continuous ECG monitor would have
possibly shown a lower success rate than Holter, in this
study, we found a significant benefit—as shown by the lower
prevalence of AF over time (adjusted RR: 0.18; 95% CI:
0.07 to 0.44; p  0.001)—when the “extensive” approach
was used.
Interestingly enough, a recent study by Albrecht et al. (6)
reported that a “limited” approach with isolation of the
pulmonary veins achieved comparable results to those of
maze III. The study, however, appears underpowered to
define the best treatment strategy for a dichotomic outcome
variable, such as the recovery of SR; furthermore, no
patients underwent Holter monitoring during follow-up
either. Moreover, from an anatomic point of view, Chauvin
et al. (7) observed in explanted hearts striated muscle around
the coronary sinus connecting the inferior right atrium to
the LA, which may account for the inconsistent results
reported whenever the isolated LA lesion set is chosen.
From an electrophysiologic point of view, Lammers et al.
(8) first showed that the LA refractory period is shorter than
the right. Given that AF can persist in an enlarged right
Figure 3 Kaplan-Meier Curves for Combined Event-Free Surviva
Freedom from combined death/hospitalization are reported according to the 5 diffatrium (9), it can be speculated that an isolated left-sidedprocedure may suffice to prevent recurrence in patients with
normal atria, owing to the shorter refractory periods of the
LA. On the other hand, additional right atrial ablation lines
will be required in patients with enlarged atria (8), as is
often encountered in the cardiac surgical population. Fur-
thermore, Lin et al. (10) have recently demonstrated with a
map-guided approach that paroxysmal AF may be induced
in specific right atrial “trigger zones,” where ablation elim-
inates AF. Therefore, it is not surprising that previous
surgical experiences have reported superior results with the
adjunct of right atrial ablation procedures (3,11,12). More
recently, the results from the International Registry of Atrial
Fibrillation Surgery reported a biatrial approach to be
predictive of SR restoration at 5 years’ follow-up (2). We
were not able to confirm an improved electrophysiologic
outcome at 6 months with the “extended” approach associ-
ated with GP isolation or when introducing 4 linear
ablations. A better clinical outcome (combined event of death
and hospitalization) was shown with the addition of the 4
linear ablation approaches but not with the addition of GP
isolation. These findings, originating from subgroup analy-
ses, are to be considered with due caution.
It is recognized that unipolar ablation carries the risk for
incomplete “nontransmural” lesions (1,3), mostly because
none of the unipolar devices provide the surgeon with
feedback relative to transmurality (3). In 2008, Benussi et al.
(13) demonstrated the safety and efficacy of a complete
bipolar radiofrequency ablation, with superior results com-
pared with those of the unipolar devices. Accordingly, we
ording to 5 Different Surgical Treatment Arms
urgical treatment arms.l, Acc
erent sreport here a significant improvement of electrophysiologi-
Relative
Heart
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unipolar to bipolar LA ablation. Despite bipolar clamping
integrated by the measurement of conductance solving the
shortcomings of the unipolar device (3), it has been shown
that not all of the lesions produce conduction block (14).
Studies have shown that gaps even smaller than 1 mm can
allow the propagation of AF (15). Moreover, although
isolation of the pulmonary veins can be tested intraopera-
tively, the remaining lesions cannot be verified, thus leaving
the potential for incomplete transmurality (14). Finally, the
so-called maze procedures with alternative energy sources all
leave less isolated LA tissue compared with the Cox-maze
procedures (14). The critical role of transmurality has been
recently stressed by Albrecht et al. (6), showing significantly
better results with surgical pulmonary vein isolation com-
pared with transcatheter ablation. All of these data led us to
empirically move toward the 4-time repetition of each line
of ablation. Indeed, subgroup B3 showed the highest
freedom from AF/AFL/AT, although the study was not
sufficiently powered for sound conclusions from subgroup
analyses.
The 2 groups also showed significant differences in terms
of follow-up prevalence of NYHA functional class II/III;
Longitudinal Assessment of Treatment Outcome: Post-Hoc ComparTable 2 Longitudinal Assessment of Treatment Outcome: Post
Outcome
Time
(Months)
Number Available
(“Limited”/“Extensive”)
“Ex
A
AF
Discharge 32/105
3 32/105 2
6 32/105
12 31/102 1
18 29/64 1
24 26/51
NYHA functional class II/III
Discharge 32/105 1
3 32/105 2
6 32/105 1
12 31/102 1
18 29/64 1
24 26/51
E/A recovery
3 11/83 6
6 21/95 7
12 17/83 7
18 14/52 4
24 14/42 3
Use of antiarrhythmic drugs
Discharge 32/105 10
3 32/105 10
6 32/105 10
12 31/102 4
18 29/64 2
24 26/51 1
*Experiment-wise 95% CI (corrected for 6 comparisons). †Significant after Bonferroni correction.
AF  atrial fibrillation; CI  confidence interval; E/A  ratio of E- to A-wave; NYHA  New Yorkuse of antiarrhythmic drugs; and freedom from overallhospitalization, hospitalization for CHF, and combined
death/hospitalization. In particular, we found a significant
reduction in follow-up NYHA functional class II/III at all
time points (except for the third post-operative month,
possibly because of a still ongoing recovery), together with a
lower freedom from CHF in the “limited” approach. In
addition, it is noteworthy that the use of antiarrhythmic
drugs was less common in the “extensive” lesion set in the
late follow-up period, thus suggesting a more “stable”
restoration of SR. On the other hand, it has to be kept in
mind that the decision to stop antiarrhythmic drugs in our
series was left to the treating physician (cardiologists or
general practitioners), therefore precluding the possibility to
understand whether the antiarrhythmic treatment was
stopped because patients were in SR or SR was present
because patients were still on treatment.
Different studies have demonstrated that conversion to
SR resulted in reverse remodeling of atrial diameters,
volumes, and function (2,4). These data, together with the
demonstration of an improved shuttle walk distance and a
reduction in the levels of plasma brain natriuretic peptide
(15), further confirmed those of Stulak et al. (16) and
demonstrated a better functional status whenever SR was
of Prevalence at Each Time PointComparison of Prevalence at Each Time Point
e” “Limited”
Ablation RD (99.2% CI)* p Value†
8 (25%) 20% (41% to 0%) 0.002†
) 20 (62%) 43% (68% to18%) 0.001†
8 (25%) 17% (39% to 4%) 0.012
) 11 (35%) 19% (44% to 6%) 0.042
) 12 (41%) 26% (53% to 1%) 0.008†
) 10 (38%) 23% (51% to 6%) 0.044
) 16 (50%) 36% (61% to10%) 0.001†
) 14 (44%) 23% (48% to 3%) 0.020
) 13 (41%) 24% (49% to 0%) 0.005†
) 16 (52%) 38% (63% to12%) 0.001†
) 15 (52%) 24% (62% to7%) 0.001†
) 12 (46%) 29% (58% to 0%) 0.008†
) 5 (45%) 36% (5% to 77%) 0.014
) 12 (57%) 26% (4% to 56%) 0.016
) 13 (76%) 16% (12% to 45%) 0.064
) 11 (79%) 12% (19% to 43%) 0.351
) 12 (86%) 5% (23% to 32%) 0.633
%) 32 (100%) — —
%) 32 (100%) — —
%) 32 (100%) — —
) 24 (77%) 31% (55% to7%) 0.002†
) 19 (65%) 33% (61% to5%) 0.003†
) 15 (58%) 34% (64% to4%) 0.003†
risks and 95% CIs from the log linear models are reported in the text.
Association; RD  risk difference.ison-Hoc
tensiv
blation
5 (5%)
0 (19%
8 (8%)
7 (17%
0 (16%
8 (16%
5 (14%
2 (21%
7 (16%
4 (14%
1 (17%
9 (17%
8 (82%
9 (83%
7 (93%
7 (90%
8 (90%
5 (100
5 (100
5 (100
7 (46%
1 (33%
2 (23%restored, regardless of the underlying valve disease. There-
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correlated better functional status, it is not surprising that
the “extensive” group also showed better freedom from
overall hospitalization, better freedom from hospitalization
for heart failure, and significantly better freedom from
combined death/hospitalization.
Finally, the risk has been recently claimed for reduced
atrial contractility after maze procedures (5,17). Yuda et al.
(5) reported a reduced LA filling fraction 12 months after
modified maze surgery. Incisions of the LA wall and
excision of the LA appendage may contribute to the
decreased LA contractility (5). Nonphysiological coupling
of atrioventricular contractions caused by delayed LA acti-
vation may also contribute to these results (17). Moreover,
after Cox-maze III surgery for paroxysmal AF, Lönnerholm
et al. (18) demonstrated that LA and right atrial contrac-
tility were significantly reduced after 6 and 56 months versus
Figure 4 Prevalence in the Use of Antiarrhythmic Drugs Over F
Patients without (A) and with (B) atrial fibrillation (AF) at the time of assessment.baseline. The initial reduction in the atrial areas wasproposed to depend on atrial scarring owing to extensive
surgery, but the later deterioration of atrial dimensions and
function was unexpected in patients with SR (18). Despite
these reports contrasting with others showing functional
atrial recovery (4,16,19), we found comparable results in
terms of recovery of E/A at longitudinal analysis between
the 2 groups, thus suggesting a comparable recovery of atrial
kick between the “extensive” and “limited” groups, regard-
less of the extension of atrial scars.
Study limitations. The main limitation of the study is the
fact that patients were accrued sequentially and the lesion set
evolved over time, thus limiting the follow-up length of the last
ablative strategy. The lack of randomization to treatment is
another. The use of analyses stratified by the propensity score
partially obviate this, however, because unmeasured confound-
ers were not accounted for. Moreover, different associated
cardiac diseases affected the study population. Therefore, ran-
-Up Assessments From 3 to 24 Monthsollowdomized controlled trials are necessary to further clarify the
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February 22, 2011:931–40 AF Ablation With Different Lesion Setsbest achievable lesion set. Also, the study was not powered for
sound subgroup comparisons, and all findings derived from
these are to be considered as descriptive only. Nonetheless,
they might provide indications for future research protocols.
Further, the low event rate (although a favorable outcome for
the patient) hampers extensive multivariable modeling. In this
series, however, the low event rate was in part overcome by
performing most analyses while adjusting for AF at declamp
and stratifying on the propensity score. The propensity score
was constructed as a measure of the propensity to use either the
“limited” or “extensive” approach based on all patients’ pre- and
peri-operative characteristics.
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